Old Web
English
Sign In
Acemap
>
authorDetail
>
Joel L. Johnson
Joel L. Johnson
GlaxoSmithKline
Darapladib
Placebo
Internal medicine
Medicine
Cardiology
4
Papers
328
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Effect of Darapladib Treatment on Endarterectomy Carotid Plaque Lipoprotein-Associated Phospholipase A2 Activity: A Randomized, Controlled Trial
2014
PLOS ONE
Joel L. Johnson
Yi Shi
Rose Snipes
Salim Janmohamed
Timothy E. Rolfe
Bill Davis
Anthony D. Postle
Colin H. Macphee
Show All
Source
Cite
Save
Citations (20)
Peripheral artery disease, biomarkers, and darapladib
2011
American Heart Journal
Jeffrey S. Berger
Christie M. Ballantyne
Michael Davidson
Joel L. Johnson
Elizabeth Tarka
Denise Lawrence
Trupti Trivedi
Andrew A. Zalewski
Emile R. Mohler
Show All
Source
Cite
Save
Citations (20)
Study design and rationale for the Stabilization of pLaques usIng Darapladib—Thrombolysis in Myocardial Infarction (SOLID-TIMI 52) trial in patients after an acute coronary syndrome
2011
American Heart Journal
Michelle L. O'Donoghue
Eugene Braunwald
Harvey D. White
Patrick W. Serruys
Ph. Gabriel Steg
Judith S. Hochman
Aldo P. Maggioni
Christoph Bode
Douglas Weaver
Joel L. Johnson
Greg Cicconetti
Mary Ann Lukas
Elizabeth Tarka
Christopher P. Cannon
Show All
Source
Cite
Save
Citations (85)
The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study.
2008
Journal of the American College of Cardiology
Emile R. Mohler
Christie M. Ballantyne
Michael Davidson
Markolf Hanefeld
L. M. Ruilope
Joel L. Johnson
Andrew A. Zalewski
Show All
Source
Cite
Save
Citations (203)
1